<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26143" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Olanzapine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thomas</surname>
            <given-names>Kristina</given-names>
          </name>
          <aff>American University of Antigua</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristina Thomas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26143.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Olanzapine is a second-generation (atypical) antipsychotic medication. The FDA has approved this medication for schizophrenia if the patient is over the age of 13 and bipolar disorder, including mixed or manic episodes. Olanzapine is also approved for use with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), in patients with episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression. It is important to note that olanzapine is not FDA-approved for patients under the age of 13. In addition, the combination of olanzapine with fluoxetine is not approved for patients under the age of 10. This activity covers olanzapine, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, contraindications, and monitoring, and highlights the role of the interprofessional team in the management of olanzapine therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of olanzapine.</p></list-item><list-item><p>Summarize the approved and off-label indications for olanzapine therapy.</p></list-item><list-item><p>Review the adverse event profile for olanzapine.</p></list-item><list-item><p>Outline the importance of collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from therapy with olanzapine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26143&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26143">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26143.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Olanzapine is a second-generation (atypical) antipsychotic medication. FDA has recently approved olanzapine in combination with samidorphan to&#x000a0;attenuate olanzapine-induced weight gain.&#x000a0;<xref ref-type="bibr" rid="article-26143.r1">[1]</xref></p>
        <p>
<bold>&#x000a0;FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Schizophrenia if the patient is over the age of 13 years</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bipolar I disorder, for acute treatment of manic or mixed episodes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Olanzapine also has approval for use with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), in patients with episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression. It is essential to&#x000a0;recognize&#x000a0;that olanzapine is not FDA-approved for patients under the age of thirteen years. The combination of olanzapine with fluoxetine does not have approval for patients under the age of 10 years.<xref ref-type="bibr" rid="article-26143.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The FDA has recently approved olanzapine in combination with samidorphan to&#x000a0;attenuate olanzapine-induced weight gain for schizophrenia and bipolar I disorder.<xref ref-type="bibr" rid="article-26143.r1">[1]</xref><xref ref-type="bibr" rid="article-26143.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-label Clinical Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute agitation<xref ref-type="bibr" rid="article-26143.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Delirium<xref ref-type="bibr" rid="article-26143.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anorexia nervosa<xref ref-type="bibr" rid="article-26143.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chemotherapy-induced nausea and vomiting (CINV)<xref ref-type="bibr" rid="article-26143.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26143.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Olanzapine is an atypical (second-generation) antipsychotic that exerts its action primarily on dopamine and serotonin receptors. It works on dopamine D2 receptors in the mesolimbic pathway as an antagonist,&#x000a0;blocking dopamine from potential action at the post-synaptic receptor. Olanzapine binds loosely to the receptor and dissociates easily, allowing for normal dopamine neurotransmission.</p>
        <p>The effect on the D2 receptors&#x000a0;leads to a decrease in positive symptoms in patients, including hallucinations, delusions, and disorganized speech, thought, and behavior. Olanzapine works similarly on serotonin 5HT2A receptors in the frontal cortex as an antagonist.</p>
        <p>The effect of olanzapine&#x000a0;on serotonin decreases negative symptoms, including anhedonia, flat affect, alogia, avolition, and poor attention.<xref ref-type="bibr" rid="article-26143.r8">[8]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption: Daily administration of olanzapine leads to reaching the steady-state plasma concentration in about one week. The time to peak concentration is 6 hours for oral formulation and 15-45 minutes for IM formulation. Olanzapine has a half-life of 21 to 54 hours, with an average of 30 hours.<xref ref-type="bibr" rid="article-26143.r9">[9]</xref></p>
        <p>Distribution: The volume of distribution is approximately 1000 liters, and the medication is distributed widely throughout the body. It is 93% bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein.</p>
        <p>Metabolism:&#x000a0;Olanzapine is extensively metabolized by the liver&#x000a0;by glucuronidation and the cytochrome P450 system. This system's enzymes that metabolize olanzapine are primarily&#x000a0;CYP1A2 and, minorly, CYP2D6. CYP1A2 genes are poly-morphic; however, a study showed no reported associations between various polymorphisms and pharmacokinetics of the medication.<xref ref-type="bibr" rid="article-26143.r10">[10]</xref><xref ref-type="bibr" rid="article-26143.r11">[11]</xref></p>
        <p>Excretion: The half-life of olanzapine is approximately 30 hours (varies between 21 to 54 hours). Olanzapine&#x000a0;is excreted&#x000a0;primarily&#x000a0;via the renal route (57%) and feces (30%).&#x000a0;</p>
      </sec>
      <sec id="article-26143.s4" sec-type="Administration">
        <title>Administration</title>
        <p>A significant benefit of olanzapine is its multiple routes of administration, giving it potential use in many&#x000a0;patients.</p>
        <p>It is available in tablet form, which is beneficial in compliant patients who can take medications orally. The tablet form is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg dosages. In addition, olanzapine is also available in a disintegrating tablet form. This form is especially beneficial for patients who cannot swallow pills but wishes to take an oral form, patients who have an aversion to taking medications by not swallowing the tablet, or those who are agitated.&#x000a0;The bioavailability of orodispersible forms has been found to be considerably greater than their standard dosage forms.</p>
        <p>Olanzapine is also available in an injectable dosage of 5 mg/mL. This form may be best for the agitated patient who is not medication compliant and refuses or cannot swallow the oral formulation of the drug.</p>
        <p>Clinicians should monitor patients for post-injection delirium/sedation syndrome&#x000a0;with extended-release olanzapine injections.<xref ref-type="bibr" rid="article-26143.r12">[12]</xref></p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Patients with Hepatic impairment:&#x000a0;</bold>Patients with hepatic impairment do not require a dosage adjustment. Patients with Child-Pugh Classification A and B cirrhosis did not majorly influence the metabolism of this medication. Because of this extensive metabolism of olanzapine, only 7% of the drug remains unchanged upon excretion. However, olanzapine&#x000a0;can increase aminotransferase levels; hence use with caution in&#x000a0;patients with hepatic impairment.<xref ref-type="bibr" rid="article-26143.r13">[13]</xref></p>
        <p><bold>Patients with Renal Impairment: </bold>Patients with renal impairment do not require special dosing for this medication because of its metabolism.<xref ref-type="bibr" rid="article-26143.r14">[14]</xref>&#x000a0;However, it is important to&#x000a0;recognize that olanzapine is not removed by hemodialysis.</p>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>Extrapyramidal symptoms, feeding disorders, and respiratory distress have been documented in neonates exposed to olanzapine during the third trimester of pregnancy. Monitor neonates for extrapyramidal or withdrawal symptoms, as some neonates need prolonged hospitalization while others recover spontaneously. However, there is a risk to the pregnant mother from untreated schizophrenia or bipolar disorder, including the risk of relapse, deterioration leading to hospitalization, and suicide. Schizophrenia and bipolar disorder are also associated with increased adverse perinatal outcomes. Consequently, olanzapine may be used for bipolar disorders and schizophrenia, but the clinician needs to carefully evaluate the risk-benefit in consultation with an obstetrician and psychiatrist.<xref ref-type="bibr" rid="article-26143.r15">[15]</xref></p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Higher maternal doses of olanzapine produce low concentrations in human milk and trace levels in the serum of breastfed infants. Sedation is the major adverse drug reaction in infants. Systematic reviews of second-generation antipsychotics concluded that olanzapine is the preferred agent during breastfeeding.<xref ref-type="bibr" rid="article-26143.r16">[16]</xref>&#x000a0;In addition, a new safety scoring system (use of psychotropic drugs during lactation) finds olanzapine acceptable during breastfeeding.<xref ref-type="bibr" rid="article-26143.r17">[17]</xref></p>
        <p><bold>Pharmacogenetic Considerations: </bold>Smokers may need a 30%&#x000a0;higher&#x000a0;daily dose than nonsmokers&#x000a0;due to&#x000a0;CYP1A2 induction, per American Psychiatric Association(APA) guideline 2020.<xref ref-type="bibr" rid="article-26143.r9">[9]</xref></p>
      </sec>
      <sec id="article-26143.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>One of the most common adverse effects of olanzapine is the potential for weight gain. Olanzapine causes an increase in appetite leading to hyperphagia with a consequence of weight gain.<xref ref-type="bibr" rid="article-26143.r18">[18]</xref>&#x000a0;Therefore, it should be used cautiously in patients who are obese, have little control over their food intake, and do not exercise regularly to combat weight gain.<xref ref-type="bibr" rid="article-26143.r19">[19]</xref></p>
        <p>Another adverse effect of olanzapine is the increased risk of metabolic effects. Olanzapine has a high potential to cause reduced insulin sensitivity, leading to impaired glucose tolerance, especially in a younger population.<xref ref-type="bibr" rid="article-26143.r20">[20]</xref> While an exact mechanism for these adverse effects is still under debate, evidence suggests that the WNT signaling pathway effector TCF7L2 plays a vital role in glucose homeostasis.&#x000a0;Olanzapine-induced weight gain and decreased insulin sensitivity lead to increased expression of TCF7L2 in the liver and skeletal muscle. Elevated insulin levels lead to increased expression of TCF7L2 in adipose tissue. This increased expression of TCF7L2 in multiple body tissues, which all play a role in glucose metabolism, suggests the mechanism for metabolic dysfunction caused by olanzapine. This finding also contributes to a possible therapeutic target to prevent or treat the adverse metabolic effects of olanzapine.<xref ref-type="bibr" rid="article-26143.r21">[21]</xref></p>
        <p>Olanzapine's mechanism of action also lends itself to directly causing adverse reactions associated with the dopaminergic blockade. Patients have an increased risk of developing akathisia, extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome. However, the risk of developing these side effects is lesser than first-generation antipsychotics due to the lower affinity and rapid dissociation of olanzapine with the D2 receptors.<xref ref-type="bibr" rid="article-26143.r8">[8]</xref></p>
        <p>Hematological abnormalities such as neutropenia and thrombocytopenia are reported.<xref ref-type="bibr" rid="article-26143.r22">[22]</xref><xref ref-type="bibr" rid="article-26143.r23">[23]</xref><bold>&#x000a0;</bold>Post-marketing surveillance has also reported cases of hypothermia and edema due to olanzapine.<xref ref-type="bibr" rid="article-26143.r24">[24]</xref></p>
        <p>Samidorphan, a &#x003bc;-opioid receptor antagonist, is approved to reduce olanzapine-associated weight gain.<xref ref-type="bibr" rid="article-26143.r25">[25]</xref><xref ref-type="bibr" rid="article-26143.r26">[26]</xref></p>
      </sec>
      <sec id="article-26143.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Olanzapine is contraindicated in patients with a known hypersensitivity to this medication or medications in its class. There is a boxed warning for olanzapine regarding dementia-related psychosis. Elderly patients with dementia who present with symptoms of psychosis should not be prescribed olanzapine due to an increased mortality risk due to increased risk of heart failure, sudden death due to cardiac causes, and pneumonia.<xref ref-type="bibr" rid="article-26143.r27">[27]</xref>&#x000a0;Concomitant use of parenteral olanzapine(high dose) with benzodiazepines is not advised due to&#x000a0;sedation and the risk of severe cardiorespiratory depression.<xref ref-type="bibr" rid="article-26143.r9">[9]</xref>&#x000a0;</p>
        <p>Additionally, due to the adverse effects of weight gain and metabolic dysfunction, clinicians should use this medication with caution in patients who are obese or have diabetes mellitus. However, using olanzapine is not an absolute contraindication in these patients.<xref ref-type="bibr" rid="article-26143.r18">[18]</xref></p>
      </sec>
      <sec id="article-26143.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring blood glucose levels frequently and educating patients on exercise and diet should follow a prescription for olanzapine.<xref ref-type="bibr" rid="article-26143.r28">[28]</xref>&#x000a0;The optimal therapeutic window for olanzapine is 20 ng/mL to 40 ng/mL. A serum concentration of 80 ng/mL is the threshold for adverse reactions to olanzapine. Toxicology&#x000a0;studies identified that postmortem serum levels of olanzapine were higher than antemortem levels, and high dosages of olanzapine were only lethal when combined with another drug.<xref ref-type="bibr" rid="article-26143.r29">[29]</xref><xref ref-type="bibr" rid="article-26143.r30">[30]</xref></p>
        <p>Clinicians should monitor patients while discontinuing&#x000a0;olanzapine therapy, as there is a risk of&#x000a0;physical withdrawal and rebound symptoms. Hence olanzapine should be tapered gradually.<xref ref-type="bibr" rid="article-26143.r31">[31]</xref>&#x000a0;Olanzapine (long-acting IM formulation):&#x000a0;There is a&#x000a0;risk of post-injection delirium syndrome with olanzapine; therefore, it must be&#x000a0;administered in a registered health care facility with ready access to emergency services; the patient requires&#x000a0;monitoring for at least 3 hours&#x000a0;after administration.<xref ref-type="bibr" rid="article-26143.r9">[9]</xref></p>
      </sec>
      <sec id="article-26143.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Olanzapine has a&#x000a0;low potential for toxicity when prescribed alone. However, there are case reports which found&#x000a0;olanzapine toxicity caused by high doses of the medication when taken in conjunction&#x000a0;with other medicines. For example, a case report&#x000a0;of a patient who overdosed by taking 560 milligrams of olanzapine in addition to 6.4 grams of propranolol and 280 milligrams of amlodipine had extreme hypotension, circulatory collapse, respiratory depression, and coma.<xref ref-type="bibr" rid="article-26143.r32">[32]</xref></p>
        <p>According to the product labeling and postmarketing&#x000a0;reports, the following are the features of olanzapine toxicity.<xref ref-type="bibr" rid="article-26143.r28">[28]</xref></p>
        <p>Serum concentration of olanzapine &#x0003e;0.1 mg/L is toxic and serum concentration&#x0003e;1 mg/L can be fatal.<xref ref-type="bibr" rid="article-26143.r28">[28]</xref></p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Agitation</p>
          </list-item>
          <list-item>
            <p>Dysarthria</p>
          </list-item>
          <list-item>
            <p>Tachycardia and hypotension</p>
          </list-item>
          <list-item>
            <p>Extrapyramidal symptoms</p>
          </list-item>
          <list-item>
            <p>Sedation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Miosis<xref ref-type="bibr" rid="article-26143.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Aspiration</p>
          </list-item>
          <list-item>
            <p>Delirium</p>
          </list-item>
          <list-item>
            <p>Respiratory depression</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
          <list-item>
            <p>Convulsions</p>
          </list-item>
          <list-item>
            <p>Ventricular dysrhythmia<xref ref-type="bibr" rid="article-26143.r34">[34]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>There is no specific antidote&#x000a0;to olanzapine. In acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation, including intubation. In addition, clinicians should consider the possibility of multiple drug involvement.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In addition, gastric lavage (after intubation, if the patient is unconscious) and administration of activated charcoal with a laxative should be considered. The administration of activated charcoal (1&#x000a0;g) reduced the Cmax and AUC of oral olanzapine by about 60%. As peak olanzapine levels are not typically obtained until about 6 hours after dosing, charcoal may be a valuable treatment for olanzapine overdose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis. Therefore, cardiovascular monitoring should commence immediately and include continuous electrocardiographic monitoring to detect possible arrhythmias.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypotension and circulatory collapse should be treated with appropriate measures; intravenous fluids and sympathomimetic agents. Do not use epinephrine, dopamine, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension in the setting of the olanzapine-induced alpha blockade.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Close medical supervision and monitoring should continue until the patient recovers.<xref ref-type="bibr" rid="article-26143.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26143.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Olanzapine is one of the most commonly used medications in episodes of psychosis.<xref ref-type="bibr" rid="article-26143.r36">[36]</xref>&#x000a0;As mentioned above, the half-life of olanzapine is the same among all three forms of administration. Thus, it should not influence the decision of which route of administration to choose. Consequently, ethics plays a significant role when discussing the chosen route of administration for olanzapine.</p>
        <p>From a clinical standpoint, the injection form may be the preferred route when dealing with an agitated patient who does not wish or cannot swallow a pill; however, a provider should not subject a patient to injection if they do not&#x000a0;need it. Strong interpersonal communication skills are necessary when working with an uncooperative or agitated patient. If the patient can consume the dissolving form of olanzapine, this route of administration should merit consideration over the injectable form.</p>
        <p>The prescribing clinician should work closely with specialists, the pharmacy, and the nursing staff in patients receiving olanzapine. Nursing staff will administer the medication in the most controlled circumstances; they should be alert to patients refusing to take the drug and watch for its adverse effects.&#x000a0;In this&#x000a0;scenario, specialty-trained psychiatry nurses can contribute as they are more familiar with monitoring parameters.&#x000a0;Pharmacists should carefully vet the patient's medication regimen, looking for red flags for drug interactions. A board-certified psychiatric pharmacist can participate in agent selection and dosing with the clinicians. Clinicians should be familiar with the fact that long-acting intramuscular olanzapine carries a substantial risk of delirium. Hence, it is only available through the FDA REMS(Risk Evaluation and Mitigation Strategy) program.<xref ref-type="bibr" rid="article-26143.r37">[37]</xref><xref ref-type="bibr" rid="article-26143.r38">[38]</xref></p>
        <p>In the case of an overdose, emergency department physicians should ensure a patent airway, breathing, and circulation. Similarly, critical care physicians and ICU nurses can play a vital role in cases of severe overdose. Finally, psychiatry referral is crucial in the case of intentional overdose. As illustrated above, clinicians (MDs, DOs, NPs, PAs), specialists, pharmacists, nurses, and other healthcare providers are involved in taking care of the patient. Therefore, all the healthcare&#x000a0;providers working in an interprofessional team&#x000a0;should collaborate closely so that the patient on olanzapine receives the maximum benefit with minimal adverse effects, resulting in optimal patient outcomes.&#x000a0;</p>
        <p>APA guidelines recommend that patients with schizophrenia receive assertive community treatment (ACT) if there is poor compliance with treatment. For ACT to be successful, a multidisciplinary strategy is necessary in which patients receive individualized care&#x000a0;from clinicians, psychiatrists, nurses, social workers, and case managers. Patients with poor compliance may benefit from considering a long-acting injectable (LAI) antipsychotic medication like olanzapine.&#x000a0;Studies suggest that assertive community treatment with an interprofessional&#x000a0;team-based approach is associated with improved&#x000a0;quality of life, and patients are less&#x000a0;likely to be hospitalized.<xref ref-type="bibr" rid="article-26143.r9">[9]</xref><xref ref-type="bibr" rid="article-26143.r39">[39]</xref>&#x000a0;[Level 1]</p>
      </sec>
      <sec id="article-26143.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26143&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26143">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26143/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26143">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26143.s11">
        <title>References</title>
        <ref id="article-26143.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monahan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gums</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.</article-title>
            <source>Ann Pharmacother</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>56</volume>
            <issue>9</issue>
            <fpage>1049</fpage>
            <page-range>1049-1057</page-range>
            <pub-id pub-id-type="pmid">35040357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>9</issue>
            <fpage>1299</fpage>
            <page-range>1299-306</page-range>
            <pub-id pub-id-type="pmid">18759541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Serdenes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Citrome</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?</article-title>
            <source>Expert Rev Neurother</source>
            <year>2022</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>365</fpage>
            <page-range>365-376</page-range>
            <pub-id pub-id-type="pmid">35354374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Pepper</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Holloman</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Feifel</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup.</article-title>
            <source>West J Emerg Med</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-34</page-range>
            <pub-id pub-id-type="pmid">22461918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Narasimhan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options.</article-title>
            <source>Psychiatry (Edgmont)</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>10</issue>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">19724721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Attia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Steinglass</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schreyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wildes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Guarda</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial.</article-title>
            <source>Am J Psychiatry</source>
            <year>2019</year>
            <month>Jun</month>
            <day>01</day>
            <volume>176</volume>
            <issue>6</issue>
            <fpage>449</fpage>
            <page-range>449-456</page-range>
            <pub-id pub-id-type="pmid">30654643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adel</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies.</article-title>
            <source>Am J Manag Care</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>14 Suppl</issue>
            <fpage>S259</fpage>
            <page-range>S259-S265</page-range>
            <pub-id pub-id-type="pmid">28978206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tollens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Risterucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>K&#x000fc;nnecke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lebhardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reinwald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weber-Fahr</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Meyer-Lindenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sartorius</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The affinity of antipsychotic drugs to dopamine and serotonin 5-HT<sub>2</sub> receptors determines their effects on prefrontal-striatal functional connectivity.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>1035</fpage>
            <page-range>1035-1046</page-range>
            <pub-id pub-id-type="pmid">30006253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anzia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lyness</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mojtabai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Servis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walaszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenzenweger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <collab>(Systematic Review)</collab>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-872</page-range>
            <pub-id pub-id-type="pmid">32867516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Na Takuathung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hanprasertpong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Teekachunhatean</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koonrungsesomboon</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>139</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-25</page-range>
            <pub-id pub-id-type="pmid">30112761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zubiaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soria-Chacartegui</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Villapalos-Garc&#x000ed;a</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gordillo-Perdomo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Abad-Santos</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The pharmacogenetics of treatment with olanzapine.</article-title>
            <source>Pharmacogenomics</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>14</issue>
            <fpage>939</fpage>
            <page-range>939-958</page-range>
            <pub-id pub-id-type="pmid">34528455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Upadhyaya</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chhabra-Khanna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Seetharama Rao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study.</article-title>
            <source>BJPsych Open</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>186</fpage>
            <page-range>186-192</page-range>
            <pub-id pub-id-type="pmid">28811926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Olanzapine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">31644149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mauri</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Paletta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Pace</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reggiori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cirnigliaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Valli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Altamura</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>12</issue>
            <fpage>1493</fpage>
            <page-range>1493-1528</page-range>
            <pub-id pub-id-type="pmid">29915922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Damkier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fenger-Gron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Skaarup</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Videbech</surname>
                <given-names>P</given-names>
              </name>
              <collab>Danish Psychiatric Society</collab>
              <collab>Danish Society of Obstetrics and Gynecology</collab>
              <collab>Danish Paediatric Society</collab>
              <collab>Danish Society of Clinical Pharmacology</collab>
            </person-group>
            <article-title>Use of psychotropic drugs during pregnancy and breast-feeding.</article-title>
            <source>Acta Psychiatr Scand Suppl</source>
            <year>2015</year>
            <issue>445</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">26344706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Olanzapine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uguz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation.</article-title>
            <source>Am J Ther</source>
            <string-date>2021 Jan-Feb 01</string-date>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>e118</fpage>
            <page-range>e118-e126</page-range>
            <pub-id pub-id-type="pmid">30601177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hou</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL/6J mice.</article-title>
            <source>Iran J Basic Med Sci</source>
            <year>2018</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>495</fpage>
            <page-range>495-501</page-range>
            <pub-id pub-id-type="pmid">29922430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2018</year>
            <month>Feb</month>
            <day>02</day>
            <volume>81</volume>
            <fpage>122</fpage>
            <page-range>122-130</page-range>
            <pub-id pub-id-type="pmid">29097257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicol</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Yingling</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Flavin</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Schweiger</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Schechtman</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Newcomer</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>75</volume>
            <issue>8</issue>
            <fpage>788</fpage>
            <page-range>788-796</page-range>
            <pub-id pub-id-type="pmid">29898210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance.</article-title>
            <source>Front Pharmacol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>379</fpage>
            <pub-id pub-id-type="pmid">29713286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carrillo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gervasini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>N&#x000fa;&#x000f1;ez</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Thrombocytopenia and fatality associated with olanzapine.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-6</page-range>
            <pub-id pub-id-type="pmid">15150680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lander</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bastiampillai</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neutropenia associated with quetiapine, olanzapine, and aripiprazole.</article-title>
            <source>Aust N Z J Psychiatry</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <pub-id pub-id-type="pmid">21058927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camilleri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fiorini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Lessons of the month 2: Olanzapine-induced hypothermia and hand oedema.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2022</year>
            <month>May</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-286</page-range>
            <pub-id pub-id-type="pmid">35584835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pahwa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sleem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elsayed</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Good</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>El-Mallakh</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>New Antipsychotic Medications in the Last Decade.</article-title>
            <source>Curr Psychiatry Rep</source>
            <year>2021</year>
            <month>Nov</month>
            <day>29</day>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>87</fpage>
            <pub-id pub-id-type="pmid">34843030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <article-title>Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2021</year>
            <month>Nov</month>
            <day>29</day>
            <volume>63</volume>
            <issue>1638</issue>
            <fpage>191</fpage>
            <page-range>191-192</page-range>
            <pub-id pub-id-type="pmid">35085217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kales</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>After the black box warning: predictors of psychotropic treatment choices for older patients with dementia.</article-title>
            <source>Psychiatr Serv</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>1207</fpage>
            <page-range>1207-14</page-range>
            <pub-id pub-id-type="pmid">21969648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00110;or&#x00111;evi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vuk&#x0010d;evi&#x00107;</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Antunovi&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kilibarda</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ercegovi&#x00107;</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Sto&#x00161;i&#x00107;</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Vu&#x0010d;ini&#x00107;</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Olanzapine poisoning in patients treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: a brief review of serum concentrations and clinical symptoms.</article-title>
            <source>Arh Hig Rada Toksikol</source>
            <year>2022</year>
            <month>Jul</month>
            <day>07</day>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-130</page-range>
            <pub-id pub-id-type="pmid">35792773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polasek</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Sorich</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wiese</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rostami-Hodjegan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Korprasertthaworn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perera</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rowland</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>462</fpage>
            <page-range>462-476</page-range>
            <pub-id pub-id-type="pmid">29194718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urban</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Cuba&#x00142;a</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring of atypical antipsychotics.</article-title>
            <source>Psychiatr Pol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>30</day>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>1059</fpage>
            <page-range>1059-1077</page-range>
            <pub-id pub-id-type="pmid">29432503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horowitz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jauhar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Natesan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.</article-title>
            <source>Schizophr Bull</source>
            <year>2021</year>
            <month>Jul</month>
            <day>08</day>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>1116</fpage>
            <page-range>1116-1129</page-range>
            <pub-id pub-id-type="pmid">33754644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hopkins</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Sunkersing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacques</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Too many pills to swallow: A case of a mixed overdose.</article-title>
            <source>J Intensive Care Soc</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-250</page-range>
            <pub-id pub-id-type="pmid">29118840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palenzona</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kupferschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rauber-Luethy</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2004</year>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-32</page-range>
            <pub-id pub-id-type="pmid">15083933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heard</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.</article-title>
            <source>Am J Emerg Med</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>607</fpage>
            <page-range>607-16</page-range>
            <pub-id pub-id-type="pmid">19497468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Razian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pourahmad</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Analysis of Toxicity Effects of Buspirone, Cetirizine and Olanzapine on Human Blood Lymphocytes: in Vitro Model.</article-title>
            <source>Curr Clin Pharmacol</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-127</page-range>
            <pub-id pub-id-type="pmid">29766823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeisen</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Joa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Johannessen</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Opjordsmoen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Use of medication algorithms in first episode psychosis: a naturalistic observational study.</article-title>
            <source>Early Interv Psychiatry</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>503</fpage>
            <page-range>503-510</page-range>
            <pub-id pub-id-type="pmid">25588989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicholson</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yektashenas</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Risk evaluation and mitigation strategies (REMS): educating the prescriber.</article-title>
            <source>Drug Saf</source>
            <year>2012</year>
            <month>Feb</month>
            <day>01</day>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-104</page-range>
            <pub-id pub-id-type="pmid">22171604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[The Safety of Using Long-acting Injections : From an Opposing Position-Is It Better to Administer Long-acting Injections?].</article-title>
            <source>Seishin Shinkeigaku Zasshi</source>
            <year>2016</year>
            <volume>118</volume>
            <issue>8</issue>
            <fpage>584</fpage>
            <page-range>584-588</page-range>
            <pub-id pub-id-type="pmid">30620476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26143.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>McDonagh</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Dana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Selph</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Cantor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bougatsos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blazina</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Grusing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kopelovich</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Monroe-DeVita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haupt</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <source>Treatments for Schizophrenia in Adults: A Systematic Review [Internet]</source>
            <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>
            <publisher-loc>Rockville (MD)</publisher-loc>
            <year>2017</year>
            <month>10</month>
            <pub-id pub-id-type="pmid">29537779</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
